142 related articles for article (PubMed ID: 9213861)
41. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.
Friedman EA; Harris PA; Wood AJ; Stein CM; Kurnik D
Clin Pharmacol Ther; 2007 Apr; 81(4):503-9. PubMed ID: 17301734
[TBL] [Abstract][Full Text] [Related]
42. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon.
Challenor VF; Waller DG; Hayward RA; Griffin MJ; Roath OS
Angiology; 1989 Feb; 40(2):122-8. PubMed ID: 2644877
[TBL] [Abstract][Full Text] [Related]
43. A double-blind cross-over study of nifedipine retard in patients with Raynaud's phenomenon.
Finch MB; Copeland S; Passmore AP; Johnston GD
Clin Rheumatol; 1988 Sep; 7(3):359-65. PubMed ID: 3067954
[TBL] [Abstract][Full Text] [Related]
44. Nifedipine in the treatment of Raynaud's syndrome.
Aldoori M; Campbell WB; Dieppe PA
Cardiovasc Res; 1986 Jun; 20(6):466-70. PubMed ID: 3536108
[TBL] [Abstract][Full Text] [Related]
45. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
[TBL] [Abstract][Full Text] [Related]
46. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.
Gjørup T; Kelbaek H; Hartling OJ; Nielsen SL
Am Heart J; 1986 Apr; 111(4):742-5. PubMed ID: 3513504
[TBL] [Abstract][Full Text] [Related]
47. [Use of nifedipine in patients with Raynaud's phenomenon].
Rozwodowska M; Polaszewska-Muszyńska M; Ukleja-Adamowicz M; Rewakowicz M; Guzowska M; Marunowska A; Jundziłł W; Wodyńska T; Ruchalski M; Strzelecki A
Kardiol Pol; 1987; 30 Suppl():97-105. PubMed ID: 3331405
[No Abstract] [Full Text] [Related]
48. Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial.
Veness MJ; Foroudi F; Gebski V; Timms I; Sathiyaseelan Y; Cakir B; Tiver KW
Australas Radiol; 2006 Oct; 50(5):468-74. PubMed ID: 16981945
[TBL] [Abstract][Full Text] [Related]
49. Digital and radial artery blood flow in patients with Raynaud's phenomenon in response to nifedipine.
Morgan RH; Psaila JV; Davies WT; Carolan G; Woodcock JP
Eur J Vasc Surg; 1987 Dec; 1(6):403-8. PubMed ID: 3503035
[TBL] [Abstract][Full Text] [Related]
50. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.
Rodeheffer RJ; Rommer JA; Wigley F; Smith CR
N Engl J Med; 1983 Apr; 308(15):880-3. PubMed ID: 6339921
[No Abstract] [Full Text] [Related]
51. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects.
Wollersheim H; Thien T; van 't Laar A
J Clin Pharmacol; 1987 Nov; 27(11):907-13. PubMed ID: 3429697
[TBL] [Abstract][Full Text] [Related]
52. Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study.
Hirschl M; Katzenschlager R; Francesconi C; Kundi M
J Rheumatol; 2004 Dec; 31(12):2408-12. PubMed ID: 15570642
[TBL] [Abstract][Full Text] [Related]
53. Skin blood flow in patients with systemic sclerosis and Raynaud's phenomenon: effects of oral L-arginine supplementation.
Khan F; Belch JJ
J Rheumatol; 1999 Nov; 26(11):2389-94. PubMed ID: 10555898
[TBL] [Abstract][Full Text] [Related]
54. [The effect of nifedipine (Adalat) on Raynaud's phenomenon].
Baadsgaard O; Schmidt JF; Ironmann L
Ugeskr Laeger; 1983 Dec; 145(49):3814-6. PubMed ID: 6364517
[No Abstract] [Full Text] [Related]
55. Syncope and Raynaud's disease.
Guiloff RJ; Rajakulendran S; Angus-Leppan H
Arch Neurol; 2012 May; 69(5):608-13. PubMed ID: 22248476
[TBL] [Abstract][Full Text] [Related]
56. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD
Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490
[TBL] [Abstract][Full Text] [Related]
57. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
[TBL] [Abstract][Full Text] [Related]
58. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
59. [Capillaroscopic evaluation of the effects of nifedipine in patients with Raynaud's phenomenon].
Riccio A; Pennarola R; Farinaro C; Scherillo G; Infranzi E; Del Puente A; Oriente P
Clin Ter; 1988 May; 125(3):185-90. PubMed ID: 2973939
[No Abstract] [Full Text] [Related]
60. Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
Lee EY; Park JK; Lee W; Kim YK; Park CS; Giles JT; Park JW; Shin K; Lee JS; Song YW; Lee EB
Rheumatology (Oxford); 2014 Apr; 53(4):658-64. PubMed ID: 24352340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
